BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/23/2025 9:07:55 AM | Browse: 389 | Download: 790
Publication Name World Journal of Cardiology
Manuscript ID 105822
Country Pakistan
ISSN 1949-8462 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Pharmacology & Pharmacy
Manuscript Type Letter to the Editor
Article Title Finerenone and semaglutide: Role in heart failure with reduced ejection fraction
Manuscript Source Unsolicited Manuscript
All Author List Muhammad Abdul Rehman Gulzar
ORCID
Author(s) ORCID Number
Muhammad Abdul Rehman Gulzar http://orcid.org/0009-0002-0581-142X
Funding Agency and Grant Number
Corresponding Author Muhammad Abdul Rehman Gulzar, Bachelor of Medicine, Bachelor of Surgery, Multan Medical and Dental College, Multan Southern Bypass, Jahangirabad Shah Rukn E Alam Town, Multan 60000, Punjab, Pakistan. abdulrehman8104@gmail.com
Key Words Mineralocorticoid receptor antagonist; Finerenone; Semaglutide; Polypill framework; Antifibrotic; Glucagon-like peptide 1; Heart failure with preserved ejection fraction
Core Tip Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, it acts by reducing pathologic remodeling effects on heart and kidney while semaglutide improves glycemic control and improves lipid metabolism thereby regulating cardioprotective functions. Finerenone and semaglutide in combination reduces albuminuria, proinflammatory gene expression, preventing organ damage by mitigating fibrosis and inflammation, reducing obesity related cardiac remodeling and shown beneficial effects on heart failure with preserved ejection fraction by reducing preload and afterload thereby improves left ventricular function.
Publish Date 2025-05-23 09:07
Citation

Gulzar MAR. Finerenone and semaglutide: Role in heart failure with reduced ejection fraction. World J Cardiol 2025; 17(5): 105822

URL https://www.wjgnet.com/1949-8462/full/v17/i5/105822.htm
DOI https://dx.doi.org/10.4330/wjc.v17.i5.105822
Full Article (PDF) WJC-17-105822-with-cover.pdf